Meditati
Smart drugs for mental health
Our mission is to cure addiction
Modern pharma is ultra-reductionist
Single-target philosophy is ineffective for discovering safe treatments for complex disorders like addiction.
Multitarget drug design is the future
All drugs are promiscuous. We design drugs with the help of AI that target multiple pathways for superior efficacy and safety.
Leadership
William Mangione
CEO
Brennan Overhoff
Zackary Falls
Matthew Muhoberac
Gaurav Chopra
Ram Samudrala
Pipeline
Media
News
Exploring the innovative, AI-powered CANDO drug discovery platform
Our team was featured in a recent article by the Clinical and Translational Science Institute at the University at Buffalo.
Read MoreAI Applications in Healthcare: The Next Frontier
Our CEO, William Mangione, spoke at a recent LifeScienceNY event in Albany about how AI is revolutionizing healthcare.
Read More2020 NCATS ASPIRE Reduction-to-Practice Challenge Winners
All of our founders were part of the winning team for developing solutions for the opioid crisis that included faculty from MIT, UB, and Purdue.
Read MorePublications
Effective holistic characterization of small molecule effects using heterogeneous biological networks
We enhanced CANDO with multimodal data to better characterize and predict drug behavior.
Read MoreA Deep-Learning Proteomic-Scale Approach for Drug Design
We enhanced the CANDO platform to enable efficient design of new drugs using principles of multitarget philosophy.
Read Morecando.py: Open Source Software for Predictive Bioanalytics of Large Scale Drug–Protein–Disease Data
The engine powering our discovery pipeline is CANDO, an open-source drug discovery platform 15 years in the making.
Read More